Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Alessandra Saettini"'
Autor:
Chiara Cremolini, Carmen Roncero de Juan, Christine B. Boers-Doets, Kristina Vermeersch, Mieke De Wit, Jan Ouwerkerk, Alessandra Saettini, Ashley Bazin, SeeSee Juliana Raynard
Publikováno v:
Supportive Care in Cancer
Supportive Care in Cancer, 22(3), 837-846
Supportive Care in Cancer, 22(3), 837-846
Regorafenib is an oral multikinase inhibitor that has shown antitumor activity in a range of solid tumors. Based on data from phase III clinical trials, regorafenib is indicated for the treatment of adult patients with metastatic colorectal cancer wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f69353d28d34b4394904878ef0901e46
https://doi.org/10.1007/s00520-013-2085-z
https://doi.org/10.1007/s00520-013-2085-z
Autor:
Chiara Cremolini, Laura Delliponti, Alfredo Falcone, Camilla Colombo, Carlotta Antoniotti, Francesca Vannini, Marzia Pennati, Gianluca Masi, Daniele Rossini, Isa Brunetti, Nadia Zaffaroni, Beatrice Borelli, Alessandra Saettini, Serenella Gini, Federica Marmorino, Gemma Zucchelli, Filippo Pietrantonio, Roberto Moretto, Elisabetta Pfanner
Publikováno v:
Annals of Oncology. 28:vi4
675 Background: Regorafenib is a treatment option for refractory mCRC pts. Considering its limited clinical benefit and the palliative setting, patients’ selection is essential to optimize the cost-effectiveness ratio. We aimed to describe the modu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8497a1e9ca1edc8748419d9d6ea4a463
https://doi.org/10.1093/annonc/mdx422.004
https://doi.org/10.1093/annonc/mdx422.004
Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib
Autor:
Emanuela Dell'Aquila, S. Gini, M. Pellegrini, Federica Marmorino, Beatrice Borelli, Andrea Tuccoli, Lisa Salvatore, Carlotta Antoniotti, Marta Schirripa, Chiara Cremolini, I. Rizzo, Laura Poliseno, Romina D'Aurizio, Alessandra Saettini, Roberto Moretto, Alfredo Falcone, Fotios Loupakis, Daniele Rossini
Publikováno v:
ResearcherID
Annals of oncology 26 (2015). doi:10.1093/annonc/mdv233.196
info:cnr-pdr/source/autori:Schirripa, M.; Loupakis, F.; Cremolini, C.; Poliseno, L.; Salvatore, L.; Tuccoli, A.; Antoniotti, C.; D'Aurzio, R.; Marmorino, F.; Borelli, B.; Rossini, D.; Saettini, A.; Gini, S.; Moretto, R.; Rizzo, I.; Aquila, E. Dell'; Pellegrini, M.; Falcone, A./titolo:Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib/doi:10.1093%2Fannonc%2Fmdv233.196/rivista:Annals of oncology/anno:2015/pagina_da:/pagina_a:/intervallo_pagine:/volume:26
Annals of oncology 26 (2015). doi:10.1093/annonc/mdv233.196
info:cnr-pdr/source/autori:Schirripa, M.; Loupakis, F.; Cremolini, C.; Poliseno, L.; Salvatore, L.; Tuccoli, A.; Antoniotti, C.; D'Aurzio, R.; Marmorino, F.; Borelli, B.; Rossini, D.; Saettini, A.; Gini, S.; Moretto, R.; Rizzo, I.; Aquila, E. Dell'; Pellegrini, M.; Falcone, A./titolo:Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib/doi:10.1093%2Fannonc%2Fmdv233.196/rivista:Annals of oncology/anno:2015/pagina_da:/pagina_a:/intervallo_pagine:/volume:26
Introduction: Regorafenib is indicated for the treatment of mCRC patients who have failed all other therapies. Nevertheless a substantial percentage of patients experiences rapid disease progression (PD) and serious adverse events may occur. For thes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c2215535ef9bce41a71f94c0771c25d
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000365159600115&KeyUID=WOS:000365159600115
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000365159600115&KeyUID=WOS:000365159600115
